Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Esperion logo — Creative execution for today and life-saving innovation for...

Esperion

Creative execution for today and life-saving innovation for tomorrow

Founded 2008 United States Ann Arbor, United States 339 employees Post Ipo Equity Total: $852.55M Biotechnology, Health Care +1

General Information

Company Name Esperion
Founded Year 2008
Location United States Ann Arbor, United States +1
Founders / Decision Makers
Team member
Employees 339
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post Ipo Equity
Social

Get notified when Esperion moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Esperion

Esperion is an innovative biotechnology and pharmaceutical startup that is singularly focused on disrupting high cholesterol to improve overall health. Founded in 1998 and headquartered in the United States, Esperion is committed to lipid management for everybody, striving to make its medicines accessible and affordable. The company's entrepreneurial team of industry leaders is inclusive, passionate, and resourceful, reflecting its dedication to making a difference in the healthcare sector. Esperion recently secured a significant $97.80M Post-IPO Equity investment on 18 January 2024, signifying the confidence of investors in the company's mission and potential. Despite the absence of specific information regarding the investors of this substantial investment, it is evident that Esperion's innovative approach to addressing unmet needs in cholesterol management has captured the attention and support of the investment community. As a startup operating at the intersection of biotechnology, healthcare, and pharmaceuticals, Esperion's focus on developing and commercializing innovative medicines and combinations to lower cholesterol, particularly for patients with unmet needs, positions it well for potential growth and impact in the industry. With a strong emphasis on disrupting the status quo in cholesterol management, Esperion's future prospects and potential for making a meaningful difference in healthcare are worth monitoring closely. For more information, please visit esperion.com and follow the company on Twitter at www.twitter.com/EsperionInc.

Taxonomy: pharmaceutical company, drug discovery, cardiovascular diseases, metabolic diseases, high cholesterol, lipid management, HDL therapy, small molecule drugs, LDL-C, statins, innovative medicines, entrepreneurial team, patient-centric approach

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 18 Jan 2024
Post-IPO Equity •••••• - 02 Dec 2021
Post-IPO Equity •••••• 1
Investor
26 Apr 2021
Post-IPO Equity •••••• - 08 Aug 2017
Post-IPO Equity •••••• - 24 Mar 2015

View All 8 Funding Rounds

Esperion Alternatives & Competitors

Esperion vs
GenepoweRx
GenepoweRx India

Genetic Science powered by K & H

36 employees
Health Care
Esperion vs
Labrador Primary Care
Labrador Primary Care United States

Our medical practice is truly patient-centered. Our goal is to help you mentally, physically, and sp...

17 employees
Esperion vs
Think Whole Person Healthcare Aksarben
Think Whole Person Healthcare Aksarben United States

Where compassion and care come full circle.

165 employees
Also compare with: Esperion vs Pulmocide Pulmocide Esperion vs Red Mountain Weight Loss Red Mountain Weight Loss Esperion vs Neupharma Srl Neupharma Srl

FAQ About Esperion

Creative execution for today and life-saving innovation for tomorrow
Esperion was founded in 2008.
Esperion is headquartered in Ann Arbor, United States.
Esperion operates in the following industries: Biotechnology, Health Care, Pharmaceutical.
Esperion has approximately 339 employees.
Esperion has completed 8 funding rounds, raising a total of $852.55M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Esperion include GenepoweRx, Labrador Primary Care, Think Whole Person Healthcare Aksarben, Next Meats, Pulmocide. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Esperion and GenepoweRx are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Esperion and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy